- Home
- SCLX vs STEC Comparison
SCLX vs STEC Comparison
Compare SCLX & STEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- STEC
- Stock Information
- Founded
- SCLX 2011
- STEC 2006
- Country
- SCLX United States
- STEC China
- Employees
- SCLX N/A
- STEC N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- STEC
- Sector
- SCLX Health Care
- STEC
- Exchange
- SCLX Nasdaq
- STEC NYSE
- Market Cap
- SCLX 28.4M
- STEC 29.7M
- IPO Year
- SCLX N/A
- STEC 2021
- Fundamental
- Price
- SCLX $4.67
- STEC $1.18
- Analyst Decision
- SCLX Strong Buy
- STEC
- Analyst Count
- SCLX 4
- STEC 0
- Target Price
- SCLX $396.67
- STEC N/A
- AVG Volume (30 Days)
- SCLX 206.3K
- STEC 96.2K
- Earning Date
- SCLX 05-23-2025
- STEC 06-27-2025
- Dividend Yield
- SCLX N/A
- STEC N/A
- EPS Growth
- SCLX N/A
- STEC N/A
- EPS
- SCLX N/A
- STEC N/A
- Revenue
- SCLX $56,590,000.00
- STEC $260,474,693.00
- Revenue This Year
- SCLX $115.30
- STEC $9.76
- Revenue Next Year
- SCLX $73.33
- STEC $15.85
- P/E Ratio
- SCLX N/A
- STEC N/A
- Revenue Growth
- SCLX 21.07
- STEC N/A
- 52 Week Low
- SCLX $3.60
- STEC $0.20
- 52 Week High
- SCLX $80.50
- STEC $3.25
- Technical
- Relative Strength Index (RSI)
- SCLX 39.15
- STEC 50.03
- Support Level
- SCLX $3.92
- STEC $1.10
- Resistance Level
- SCLX $6.13
- STEC $1.29
- Average True Range (ATR)
- SCLX 0.69
- STEC 0.18
- MACD
- SCLX 0.13
- STEC 0.02
- Stochastic Oscillator
- SCLX 32.56
- STEC 57.14
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.